

# Frailty Predicts Incident Atrial Fibrillation in Women but Not in Men: The Kuopio Ischaemic Heart Disease Risk Factor Study

Behnam Tajik<sup>a</sup> Ari Voutilainen<sup>a</sup> Arja Lyytinen<sup>a</sup> Jussi Kauhanen<sup>a</sup>  
Gregory Y.H. Lip<sup>b,c</sup> Tomi-Pekka Tuomainen<sup>a</sup> Masoud Isanejad<sup>b,c</sup>

<sup>a</sup>Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland; <sup>b</sup>Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK; <sup>c</sup>Liverpool Centre for Cardiovascular Sciences, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, UK

## Keywords

Frailty · Arrhythmia · Atrial fibrillation · Population study

## Abstract

**Introduction:** Frailty and atrial fibrillation (AF) are common aging problems and increasing globally. The association(s) between frailty and AF has been inconclusive. The purpose of this prospective population-based cohort was to investigate the associations between frailty and incident AF in older men and women. **Methods:** In total 839 participants, women ( $n = 458$ ) and men ( $n = 381$ ), aged 61–74 years from the Kuopio Ischaemic Heart Disease Risk Factor Study were included (March 1, 1998, to December 31, 2001). At the baseline, frailty prevalence was 49.3% ( $n = 414$ ), and non-frailty 50.7% ( $n = 425$ ) of the total population. Frailty was ascertained with the presence of 3–5 and prefrailty 1–2 of the following criteria: weight loss (highest 20% over 7 years), self-reported tiredness, weakness (measured by handgrip strength), slow walking speed (walking pace), and low physical activity (lowest 20%). AF events were obtained by record linkages from the national computerized hospitalization registry in Finland up to December 31, 2019. Multivariate Cox proportional hazard regression estimated the hazard ratio (HR) of incident events, adjusted for potential confounders. **Results:** During the mean follow-up of 14.2

years, 288 AF cases (169 women; 119 men) occurred. After adjustment for possible confounders, the HRs (95% confidence intervals [CIs]) for AF was 1.46 (1.48–1.85) in the frail population, compared to the non-frail group. The association was observed only among older frail women (multi-variable-adjusted HR 1.78, 95% CI [1.28–2.48]) ( $p$  for interaction = 0.04). No statistically significant associations were observed between frailty and future AF incident among men (multivariable-adjusted HRs 1.12, 95% CI (0.77–1.63)). **Conclusions:** In this population-based epidemiological cohort, the risk of developing AF was increased in women affected by frailty at baseline but not in men.

© 2023 The Author(s).

Published by S. Karger AG, Basel

## Introduction

Frailty is an emerging global health burden, with major implications for clinical practice and older adults [1, 2]. Atrial fibrillation (AF) is the most common sustained arrhythmia seen in the clinical practice worldwide, with an estimated 6–12 million people worldwide suffering this condition in the USA by 2050 and 17.9 million people in Europe by 2060 [3]. Unsurprisingly, frailty prevalence and incidence of AF increase with age [4] and are

associated with an increased risk of mortality and morbidity from stroke, heart failure and dementia, and high healthcare costs [5–7].

There are also sex-specific differences in the epidemiology and clinical presentation of many cardiovascular disorders, including AF [8]. Evidence from large observational studies reported that AF incidence in men is higher than in women [9, 10]. The Framingham Heart Study reported that AF incidence in women is 1.6 cases per 1,000 person-years compared with 3.8 cases per 1,000 person-years in men [11]. Therefore, it would be important to investigate the risk factors of AF in an aging population on a sex-based approach.

Aging frailty is captured by the decline in biological functions, deterioration of physiological performance, reduction in the ability to respond to external stressors, and an associated increase in vulnerability [12, 13]. Indeed, frailty and AF can be understood both as consequences of biological aging and conditions that worsen biological aging. Cardiologists use frailty as an established care pathway to determine procedural risks and treatment strategies for the patient [5]. Common risk factors such as chronic inflammation have been identified for frailty and cardiovascular diseases (CVD), hospitalization [14], multimorbidity [15], and mortality [16]. A recent systematic review and meta-analysis showed a link between frailty and multimorbidity, with the latter contributing to incident AF, stroke, and other cardiovascular conditions [17–19]. Large observational studies have also indicated that frailty is highly prevalent among patients with diabetes mellitus [20], CVD [14, 21], AF [17], and heart failure [22]. One Swiss study showed that frailty predicted unplanned hospitalization, stroke, bleeding, and death in AF [23]. However, studies investigating frailty as predictor of incident AF are scarce. For example, Framingham Heart Study did not find significant association between frailty and AF, but the sex-frailty interaction was not reported [24]. In this population-based study, we investigated frailty as a predictor of AF incident in older adults in total population and by sex, utilizing data from the Kuopio Ischaemic Heart Diseases Risk Factor Study (KIHD).

## Material and Methods

The KIHD is a population-based study designed to investigate risk factors for CVD, atherosclerosis, and related outcomes in men from eastern Finland [25]. A total of 2,682 men (82.9% of those eligible) who were 42, 48, 54, or 60 years old and living in the city of Kuopio or its surrounding areas were recruited for the baseline examinations in 1984–1989. These participants underwent re-

examinations at 4 years, 11 years, and 20 years after baseline. During the 11-year follow-up examination, women were invited to join the study. The current analysis is based on 11 years of follow-up and initially comprised 2,358 participants (1,007 men and 1,351 women). Of those, 2,072 participants were found to be potentially eligible, 193 did not agree to participate, 66 did not respond to the invitation, and 39 declined to provide informed consent, which left 1,774 aged 53–74 years participants who had baseline assessments carried out between March 1998 and February 2001 [26].

The KIHD protocol was approved by the Research Ethics Committee of Kuopio University and Kuopio University Hospital on December 1, 1983 (at that time the date served as the decision reference number) and again on October 27, 1997 (the decision reference number 143/97). All the subjects signed written informed consent. Study participants were not involved in the design, conduct, reporting, or dissemination plans of the current study. Subjects with a history of AF at baseline ( $n = 54$ ) were excluded from the analyses. We also excluded participants with missing data on frailty ( $n = 881$ ), leaving 839 participants, women ( $n = 458$ ) and men ( $n = 381$ ).

### *The Assessment of AF*

All AF incident AF events that occurred from 11-year follow-up through December 31, 2019, were included. Data on events were obtained by record linkages from the national computerized hospitalization registry, which covers every hospitalization and visit in outpatient specialized healthcare in Finland (Permission THL/93/5.05.00/2013). Subjects were hospitalized because of AF or had AF when they were hospitalized for other reasons. Data on vital status were obtained from Statistics Finland (Permission TK/782/07.03.00/2021). Cardiovascular causes of AF were coded according to International Classification of Diseases codes (8th revision code 427.4, 9th revision code 427.3, and 10th revision code I48), and the accuracy was verified by a physician.

### *Frailty Ascertainment*

We have defined frailty at 11 years of follow-up using criteria developed originally by Fried and colleagues [13]. To define frailty, we used variables in five domains according to the frailty phenotype definition (handgrip strength, walking speed, physical activity, weight loss, and exhaustion) [13]. All the assessment was performed by trained nurses for KIHD study.

Handgrip strength was measured by a hand dynamometer (Martin-Balloon-Vigorimeter; Gebrüder Martin, Tuttlingen, Germany). Measurements were taken with the subjects standing in an upright position and their arms parallel to their bodies. Two measurements were taken for the dominant hand and the mean of both values was used for analysis. A one-minute resting gap was given between both handgrip measurements [27]. Study subjects belonging to the lowest quintile, separately for men and women, were considered frail and scored one for the analyses. We also applied frailty phenotype cut-offs of  $<27 \text{ kg/m}^2$  for men and  $<16 \text{ kg/m}^2$  for women but these resulted in lower  $n$  compared to the corresponding lowest quintiles. Walking speed was captured by assessing the walking speed as the mean of two attempts to walk a constant distance. Low walking speed was defined as belonging to the lowest 20%. Those belonging to low walking speed received 1 score and otherwise 0.

For the physical activity, the method of assessment and the intra-person variability of various physical activities in the KIHD were described in detail by Lakka and Salonen [28]. Briefly, data on

the total leisure-time physical activity were available for the 12-month activity history with a questionnaire modified from the Minnesota leisure-time activity questionnaire (Taylor Questionnaire). All KIH subjects were asked to fill in the frequency, duration, and intensity of each activity performed during the previous 12 months. For this study, low physical activity was defined as belonging to the lowest 20%, and those belonging to low physical activity levels received 1 score and otherwise 0.

The weight change criteria according to the frailty phenotype refer to a loss of  $\geq 5\%$  of body weight over 12 months. In these data, we used a surrogate indicating a longer term weight change for 7 years before frailty ascertainment, which may have effect on the proportion of frailty. Those belonging to the highest 20%, i.e., the highest weight changed over the past 7 years corresponded to ca.  $\geq 16\%$  change in weight. Subjects in the highest 20% of weight loss received 1 score and otherwise 0.

Self-reported exhaustion was defined by Fried and colleagues [13] using two questions from the Center for Epidemiologic Studies Depression Scale (CESD) (“I felt that anything I did was a big effort” and “I felt that I could not keep on doing things”). In the KIH data, the assessment of tiredness (exhaustion) was conducted by merging two measurements for feeling tired over the past 12 months and feeling for lack of energy over the past 12 months before frailty ascertainment at 11 years of follow-up. If the response to both questions was yes, daily, the subject received 1 score and otherwise 0. According to the frailty phenotype [13], the final frailty score was computed by adding the results from these five categories. Frailty was present for the score of 3 or more and robust for score of 0.

#### Other Measurements

Comprehensive descriptions of the sociodemographic and lifestyle characteristics, prevalent medical conditions, and use of medications have been reported previously [26]. Education and annual income were assessed using self-administered questionnaires. Dietary intakes were assessed using 4-day food recording at the time of blood sampling [29]. Body mass index (BMI) was computed as the ratio of weight in kilograms to the square of height in meters. Obesity was defined the BMI higher than 25 kg/m<sup>2</sup>.

#### Statistical Analysis

The univariate associations of frailty scores with demographic, lifestyle, and clinical characteristics at baseline were assessed by linear regression for continuous variables and  $\chi^2$  test for categorical variables. To ensure that those excluded from the study did not differ significantly for their baseline characteristics, we performed an independent sample *t* test, and results did not show any significant difference for included versus excluded subjects. Cox proportional hazard regression models were used to estimate hazard ratios (HRs) of incident events. The validity of the proportional hazard assumption was evaluated using Schoenfeld residuals, and the assumptions were met. Furthermore, the analyses were controlled for possible confounders, which were selected based on established risk factors for AF, or on associations with exposures or outcomes in the present analysis. Given the objective of our study, all analyses were conducted for men and women separately.

Two different models were used to control for confounding factors. Model 1 was adjusted for age (years), gender, and examination year. The multivariate model 2 included model 1 smoking (pack/years), years of education, intake of alcohol (grams/week), obesity, systolic and

diastolic blood pressure (mm Hg), and use of anti-hypercholesterolemia or antihypertensive medications at baseline or during follow-up (yes or no). Additional adjustment for LDL-cholesterol, HDL-cholesterol, serum triglyceride concentration, BMI, heart diseases such as ischemic heart disease, valvular disease, and heart failure, and diabetes, renal dysfunction, and sleep apnea syndrome did not materially alter the associations. Statistical significance of the interactions on a multiplicative scale was assessed by stratified analysis according to gender and likelihood ratio tests with a cross-product term. All *p* values were two-sided ( $\alpha = 0.05$ ). Data were analyzed using the SPSS software version 27 for Windows (IBM Corp.; Armonk, NY, USA).

## Results

### Baseline Characteristics

Among the 839 (458 women and 381 men) participants aged  $68.6 \pm 2.9$  years, frailty prevalence was 49.3% ( $n = 414$ ), and non-frail 50.7% ( $n = 425$ ). Table 1 shows the baseline characteristics of the entire population, women, and men. Women were older, more educated, had higher BMI, and were more often users of antihypertensive and anti-hypercholesterolemia medications, had lower physical activity, lower alcohol intake, and less likely to be smokers compared with men.

Baseline characteristics of the participants according to their frailty status are presented in Table 2. Compared with non-frail women, frail women were older, less educated, less physically active, had higher BMI, higher systolic blood pressure, consumed less alcohol, were more likely to be antihypertensive medication users, and had lower handgrip strength (Table 2). The associations were generally similar among frail men (Table 2).

### Frailty Score and AF

During a mean follow-up of 14.2 years, 288 AF cases (169 cases in women, 119 cases men) occurred. After adjustment for age, sex, and examination year, frailty was associated with higher HRs of AF (HR 1.52, 95% confidence interval (CI), 0.1.21–1.94;  $p = 0.003$ ) (model 1, Table 3). Further adjustment for potential confounders did not materially change the association (HR 1.46, 95% CI, 0.1.48–1.85;  $p = 0.002$ ) (model 2, Table 3).

We found statistically significant interactions between the women and men for frailty score ( $p$  for interaction = 0.04). We observed statistically significant associations between the frailty and risk of AF only in frail women (multivariate-adjusted HRs 1.78 [95% CI, 1.28–2.48,  $p = 2.58$ , 95% CI, 1.38–4.68,  $p = 0.001$ ]). No significant associations were observed between frailty score and risk of AF among men (multivariate-adjusted HRs 1.12, 95% CI [0.77–1.63],  $p = 0.54$ ).

**Table 1.** Baseline characteristics of the study population

Characteristic	All (n = 839)	Women (n = 458)	Men (n = 381)	Without AF (n = 551)	With AF (n = 288)
Age, years	68.6 (2.9)	68.8 (2.9)*	68.3 (2.9)	68.3 (2.9)	69.0 (2.9)*
Education, years	8.7 (3.4)	9.0 (3.4)*	8.4 (3.4)	8.8 (3.5)	8.6 (3.3)
BMI, kg/m <sup>2</sup>	28.0 (4.4)	28.7 (4.9)*	27.2 (3.5)	27.8 (4.3)	28.5 (4.4)*
Physical activity, kcal/day	178 (179)	173 (173)	183 (187)*	179 (178)	176 (183)
Obesity (%)	75.1	76.9*	72.9	73.7	77.8*
Current smoker (%)	35.1	22.9	61.7*	37	31.3
Alcohol intake, g/week	34 (72)	23 (25)	49 (97)*	36 (70)	29 (76)
Diabetes (%)	15.1	14.4	15.7	15.8	13.5
Anti-hypercholesterolemia medication (%)	6.4	7.6*	5.1	7.1	5.2
Antihypertensive medication (%)	51.2	54.6*	47.0	44.5	63.9*
Sex hormone medication (%)	13.3	24.2	0.3	14.9*	10.4
Systolic blood pressure, mm Hg	139 (18)	140 (18)	137 (18)	138 (18)	141 (18)
Diastolic blood pressure, mm Hg	80 (9)	79 (9)	81 (9)	80 (9)	80 (9)
Handgrip strength, kPA	76.0 (21.0)	75.4 (24.1)	76.6 (16.4)*	76.6 (22.6)	74.7 (17.4)
Non-frail (%)	50.7	46.5	55.6	52.3	45.1
Frail (%)	49.3	53.5	44.4	47.7	54.9

Independent sample *t* test was used to calculate means, SD, and frequency. \**p* value ≤0.05 for the comparison between genders.

**Table 2.** Baseline characteristics according to frailty status

	All participants (n = 839)		Women (n = 458)		Men (n = 381)	
	frailty status		frailty status		frailty status	
	non-frail	frail	non-frail	frail	non-frail	frail
No. of subjects (%)	425 (50.7)	414 (49.3)	213 (46.5)	245 (53.5)	212 (55.6)	169 (44.4)
Age, years	68.2 (2.9)	68.9 (2.6)*	68.4 (2.8)	69.1 (2.8)*	68.1 (2.9)	68.4 (2.4)*
Education, years	9.0 (3.6)	8.4 (2.9)*	9.3 (3.5)	8.7 (3.3)*	8.7 (3.6)	8.1 (3.2)*
Body mass index, kg/m <sup>2</sup>	27.2 (3.8)	28.8 (4.4)*	27.4 (4.1)	29.8 (5.1)*	27.1 (3.5)	27.3 (3.5)*
Physical activity, kcal/day	213 (201)	144 (147)*	207 (194)	144 (148)*	215 (208)	142 (142)*
Current smoker (%)	35.6	36.3	10.0	14.8	61.8	68.3*
Alcohol consumption, g/week	36.6 (66.8)	31.4 (77.4)	13.6 (23.9)	11.9 (26.9)*	59.4 (85.5)	59.6 (99.7)*
Diabetes (%)	13.4	16.7*	12.2	16.3	14.6	17.2
Anti-hypercholesterolemia medication (%)	7.1	5.8	8.9	6.5	5.2	4.7
Antihypertensive medication (%)	45.9	56.5*	47.4	60.8*	44.3	50.3*
Systolic blood pressure, mm Hg	139 (18)	138 (19)	140 (18)	141 (18)*	138 (18)	136 (16)
Diastolic blood pressure, mm Hg	80 (9)	79 (9)*	80 (9)	80 (8)	81 (9)	80 (8)
Handgrip strength, kPA	82.2 (22.4)	69.1 (17.8)*	82.1 (23.9)	69.6 (18.6)*	82.1 (21.6)	69.8 (16.9)*

Results being presented are mean (SD) for continuous variables and *n* (%) for categorical data. \**p* ≤ 0.05.

## Discussion

In this study, our main finding showed that the risk of developing AF during a mean follow-up of 14.2 years in those affected by frailty at baseline only in women. Data

on the association between AF and frailty have been conflicting, and previous studies conducted analysis to report frailty as a prevalent condition in patients with AF [18, 30]. Frailty also predicts mortality and length of hospitalization in AF patients [18]. Although frailty has

**Table 3.** HRs and 95% CIs for the association between frailty and incident AF

		Frailty Score	
		non-frail	frail
Total population			
AF events/participants	228/839	131/425	157/414
Model 1	–	1 (reference group)	1.52 (1.21–1.94)*
Model 2	–	1 (reference group)	1.46 (1.48–1.85)*
Women			
AF events/participants	169/458	61/213	108/245
Model 1	–	1 (reference group)	1.94 (1.22–2.67)*
Model 2	–	1 (reference group)	1.78 (1.28–2.48)*
Men			
AF events/participants	119/381	70/212	49/169
Model 1	–	1 (reference group)	1.13 (0.79–1.64)
Model 2	–	1 (reference group)	1.12 (0.77–1.63)

Model 1: adjusted for age and examination year. Model 2: adjusted for model 1 plus smoking, years of education, intake of alcohol, obesity, systolic and diastolic blood pressure, and use of anti-hypercholesterolemia or antihypertensive medications at baseline or during follow-up. *p* value ≤0.01. \*Values are hazard ratios (95% confidence interval).

been identified as an important predictor of cardiovascular outcomes [21], prospective data on the association of frailty with incident AF are scarce.

While the finding of association between frailty and AF was perhaps expected, the findings for this association being only in women were less predictable. Although many risk factors for AF have been identified in their relative effect between sexes, in contrast other important cardiovascular risk factors such as hypertension (odds ratio [OR], 1.5 in men; 1.4 in women), diabetes mellitus (OR, 1.4 in men; 1.6 in women), obesity (OR, 1.8 in men; 1.4 in women), and myocardial ischemia (OR, 1.4 in men; 1.2 in women) appear more consistent between the sexes [8, 11, 31]. The adjustment for these risk factors in our study did not materially change our findings. This study also showed a significant sex-frailty interaction, and BMI was the only significant risk factor, which was higher in women compared to men.

Our findings were in alignment with gender-specific mechanisms involved in cardiovascular and frailty development. The finding from a nationwide analysis of sex differences in patients with AF showed that women have more symptoms, more functional impairment, and worse quality of life despite less persistent from AF [32, 33]. In addition, previous studies have shown that women experience greater levels of frailty than men [34, 35]. However, the lack of a significant association in men in this study could be due to other factors such hormones and genetic exposures which can be sex-dependent and could be affecting the link between frailty in women but not men in this study.

In the Framingham Heart Study Offspring Cohort, prospective findings indicated no statistically significant association between frailty (defined by Fried phenotype and Rockwood score) and incident AF [24], while the authors of that study have used pleiotropy of aging as an explanation for this finding and suggested that AF may represent the physiologic change of aging independent of those associated with risk of frailty, and compared this with the development of cataracts, which occur as part of the normal aging process in most people [24], but also acknowledged that there are multiple common pathways for frailty and AF. They did not report whether the association was different between men and women. In contrast, Polidoro et al. [36] found that AF was strongly associated with frailty status independent of age, sex, and common diseases of elderly people. A systematic review by Guo et al. [17] concluded that frailty affects both the management and prognosis of AF in the geriatric population. Hence, the move toward a more holistic and integrated approaches to AF characterization [37] and management, based on the Atrial Fibrillation Better Care pathway [38]. Adherence to the latter has been shown to be associated with a significantly better prognosis in terms of mortality, stroke, bleeding, and hospitalizations [39–41].

Chronic inflammation is a major pathogenic factor of frailty caused by oxidative stress, hormonal, and metabolic alterations [21, 34, 42], which are systematic manifestations of atherosclerosis and cardiovascular risk

factors [43–45]. Sex differences for inflammation and frailty have also been reported [46, 47]. Higher levels of inflammatory markers have been reported in patients with AF [48, 49]. Inflammation and oxidative stress are pivotal mechanisms in the setting of hypertension, which may also promote AF [48, 49]. In addition, inflammation is an important pathophysiological mechanism of AF in patients with obesity. Obesity is associated with a higher risk of AF and frailty, and in the current study, women had higher BMI compared with men, which could potentially explain the significant association between frailty and AF.

We acknowledge that our study has limitations. Due to low number of participants in the frail category and to increase the statistical power in Cox regression analysis, frail and prefrail were grouped together. This was an observational cohort study, and although we have accounted for many confounders, residual confounding or establishing causal relations with AF and frailty cannot be excluded. Prior studies have used different measures of frailty such as Rockwood [50] or Fried [13] definitions, which can partly explain the discrepancies. AF events were low over the follow-up, we may have failed to detect true associations of smaller magnitude between AF and frailty. Given the trajectory of frailty, more participants would expect to become frail over the follow-up time, yet in our study the existing association could capture the association of frailty at baseline with AF and having frailty data for follow-up could increase the magnitude of this association but not the clinical significance.

## Conclusion

In conclusion, in this population-based epidemiological cohort, frailty was associated with incident AF in women but not in men. Further investigations into frailty and AF with longer follow-up are warranted to substantiate these results.

## References

- 1 Andrew MK, Dupuis-Blanchard S, Maxwell C, Giguere A, Keefe J, Rockwood K, et al. Social and societal implications of frailty, including impact on Canadian healthcare systems. *J Frailty Aging*. 2018; 7(4):217–23.
- 2 Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. *Lancet*. 2019;394(10206):1365–75.
- 3 Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. *Eur Heart J*. 2013;34(35):2746–51.
- 4 Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. *Europace*. 2013;15(4):486–93.
- 5 Afilalo J, Alexander KP, Mack MJ, Maurer MS, Green P, Allen LA, et al. Frailty assessment in the cardiovascular care of older adults. *J Am Coll Cardiol*. 2014;63(8):747–62.
- 6 Burdett P, Lip GY. Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs. *Eur Heart J Qual Care Clin Outcomes*. 2020;8(2):187–94.

## Statement of Ethics

The KIH D protocol was approved by the Research Ethics Committee of Kuopio University and Kuopio University Hospital on December 1, 1983 (at that time the date served as the decision reference number) and again on October 27, 1997 (the decision reference number 143/97). All the subjects signed written informed consent.

## Conflict of Interest Statement

The authors declare that they have no conflict of interest.

## Funding Sources

The present study was supported by the Päivikki and Sakari Sohlberg Foundation, Yrjö Jahnsson Foundation, Paavo Nurmi Foundation, and University of Eastern Finland (Tajik B). The KIH D project was mainly funded by research grants from the NIH and the Finnish Academy of Jukka T. Salonen and George A. Kaplan. The funding sources had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

## Author Contributions

B.T. and T.-P.T. acquired the data and designed and conducted the research; B.T. and M.I. had equal contribution in conceptualization, methodology, and writing the first draft. B.T. and A.V. worked on data curation and B.T. conducted the main data analysis. All other authors, T.-P.T., A.V., A.L., J.K., and G.Y.H.L. critically revised the manuscript for important intellectual content, writing review, and editing.

## Data Availability Statement

The KIH D data are not publicly available. The use of the KIH D data is authorized by the University of Eastern Finland (UEF). All authorizations are personal and fixed-duration. If a researcher would like to join the KIH D study group, he/she must first contact the principal investigator of KIH D at the UEF Institute of Public Health and Clinical Nutrition. Further inquiries can be directed to the corresponding author.

- 7 Zhang J, Johnsen SP, Guo Y, Lip GYH. Epidemiology of atrial fibrillation: geographic/ecological risk factors, age, sex, genetics. *Card Electrophysiol Clin*. 2021 Mar;13(1):1–23.
- 8 Andrade JG, Deyell MW, Lee AY, Macle L. Sex differences in atrial fibrillation. *Can J Cardiol*. 2018;34(4):429–36.
- 9 Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation*. 2006;114(2):119–25.
- 10 Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. *Lancet*. 2015;386(9989):154–62.
- 11 Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. *JAMA*. 1994;271(11):840–4.
- 12 Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. *Lancet*. 2013;381(9868):752–62.
- 13 Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol Med Sci*. 2001;56(3):M146–56.
- 14 Ida S, Kaneko R, Imataka K, Murata K. Relationship between frailty and mortality, hospitalization, and cardiovascular diseases in diabetes: a systematic review and meta-analysis. *Cardiovasc Diabetol*. 2019;18(1):81–13.
- 15 Ferrucci L, Fabbri E. Inflammaging: chronic inflammation in ageing, cardiovascular disease, and frailty. *Nat Rev Cardiol*. 2018;15(9):505–22.
- 16 Kojima G, Iliffe S, Walters K. Frailty index as a predictor of mortality: a systematic review and meta-analysis. *Age Ageing*. 2018;47(2):193–200.
- 17 Guo Q, Du X, Ma C. Atrial fibrillation and frailty. *J Geriatr Cardiol*. 2020 Feb;17(2):105–9.
- 18 Villani ER, Tummolo AM, Palmer K, Gravina EM, Vetrano DL, Bernabei R, et al. Frailty and atrial fibrillation: a systematic review. *Eur J Intern Med*. 2018;56:33–8.
- 19 Wilkinson C, Todd O, Clegg A, Gale CP, Hall M. Management of atrial fibrillation for older people with frailty: a systematic review and meta-analysis. *Age Ageing*. 2019;48(2):196–203.
- 20 Assar ME, Laosa O, Rodriguez Manas L. Diabetes and frailty. *Curr Opin Clin Nutr Metab Care*. 2019 Jan;22(1):52–7.
- 21 Soysal P, Arik F, Smith L, Jackson SE, Isik AT. Inflammation, frailty and cardiovascular disease. *Adv Exp Med Biol*. 2020;1216:55–64.
- 22 Wang W, Lessard DM, Saczynski J, Goldberg RJ, Go AS, Paul T, et al. Incident frailty and cognitive impairment by heart failure status in older patients with atrial fibrillation: the SAGE-AF study. *J Geriatr Cardiol*. 2020;17(11):653–8.
- 23 Gugganig R, Aeschbacher S, Leong DP, Meyre P, Blum S, Coslovsky M, et al. Frailty to predict unplanned hospitalization, stroke, bleeding, and death in atrial fibrillation. *Eur Heart J Qual Care Clin Outcomes*. 2021;7(1):42–51.
- 24 Orkaby AR, Kornej J, Lubitz SA, McManus DD, Trivison TG, Sherer JA, et al. Association between frailty and atrial fibrillation in older adults: the Framingham heart study offspring cohort. *J Am Heart Assoc*. 2021;10(1):e018557.
- 25 Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio ischaemic heart disease risk factor study. *Ann Clin Res*. 1988;20(1–2):46–50.
- 26 Kunutsor SK, Blom AW, Whitehouse MR, Kehoe PG, Laukkanen JA. Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies. *Eur J Epidemiol*. 2017;32(11):947–59.
- 27 Laukkanen JA, Voutilainen A, Kurl S, Araujo CGS, Jae SY, Kunutsor SK. Handgrip strength is inversely associated with fatal cardiovascular and all-cause mortality events. *Ann Med*. 2020;52(3–4):109–19.
- 28 Lakka TA, Salonen JT. Intra-person variability of various physical activity assessments in the Kuopio ischaemic heart disease risk factor study. *Int J Epidemiol*. 1992;21(3):467–72.
- 29 Voutilainen S, Rissanen TH, Virtanen J, Lakka TA, Salonen JT; Kuopio Ischemic Heart Disease Risk Factor Study. Low dietary folate intake is associated with an excess incidence of acute coronary events: the Kuopio Ischemic Heart Disease Risk Factor Study. *Circulation*. 2001;103(22):2674–80.
- 30 Franchi C, Antoniazzi S, Proietti M, Nobili A, Mannucci PM; SIM-AF Collaborators, et al. Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation. *Br J Clin Pharmacol*. 2018;84(9):2010–9.
- 31 Kachur S, Lavie CJ, de Schutter A, Milani RV, Ventura HO. Obesity and cardiovascular diseases. *Minerva Med*. 2017 Jun;108(3):212–28.
- 32 Kim S, Yoon S, Choi J, Kang M, Cho Y, Oh I, et al. Clinical implication of frailty assessment in older patients with atrial fibrillation. *Arch Gerontol Geriatr*. 2017;70:1–7.
- 33 Piccini JP, Simon DN, Steinberg BA, Thomas L, Allen LA, Fonarow GC, et al. Differences in clinical and functional outcomes of atrial fibrillation in women and men: two-year results from the ORBIT-AF registry. *JAMA Cardiol*. 2016;1(3):282–91.
- 34 Gordon E, Hubbard R. Physiological basis for sex differences in frailty. *Curr Opin Physiol*. 2018;6:10–5.
- 35 Shamliyan T, Talley KM, Ramakrishnan R, Kane RL. Association of frailty with survival: a systematic literature review. *Ageing Res Rev*. 2013;12(2):719–36.
- 36 Polidoro A, Stefanelli F, Ciacciarelli M, Pacelli A, Di Sanzo D, Alessandri C. Frailty in patients affected by atrial fibrillation. *Arch Gerontol Geriatr*. 2013;57(3):325–7.
- 37 Potpara TS, Lip GY, Blomstrom-Lundqvist C, Boriani G, Van Gelder IC, Heiddbuchel H, et al. The 4S-AF scheme (stroke risk; symptoms; severity of burden; substrate): a novel approach to in-depth characterization (rather than classification) of atrial fibrillation. *Thromb Haemost*. 2021;121(3):270–8.
- 38 Lip GY. The ABC pathway: an integrated approach to improve AF management. *Nat Rev Cardiol*. 2017;14(11):627–8.
- 39 Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GY. Comprehensive management with the ABC (Atrial Fibrillation Better Care) pathway in clinically complex patients with atrial fibrillation: a post hoc ancillary analysis from the AFFIRM trial. *J Am Heart Assoc*. 2020;9(10):e014932.
- 40 Romiti GF, Pastori D, Rivera-Caravaca JM, Ding WY, Gue YX, Menichelli D, et al. Adherence to the “atrial fibrillation better care” pathway in patients with atrial fibrillation: impact on clinical outcomes – a systematic review and meta-analysis of 285,000 patients. *Thromb Haemost*. 2022;122(3):406–14.
- 41 Yoon M, Yang P, Jang E, Yu HT, Kim T, Uhm J, et al. Improved population-based clinical outcomes of patients with atrial fibrillation by compliance with the simple ABC (Atrial Fibrillation Better Care) pathway for integrated care management: a nationwide cohort study. *Thromb Haemost*. 2019;119(10):1695–703.
- 42 Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. *Mech Ageing Dev*. 2007;128(1):92–105.
- 43 Karam BS, Chavez-Moreno A, Koh W, Akar JG, Akar FG. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. *Cardiovasc Diabetol*. 2017;16(1):120–9.
- 44 Korantzopoulos P, Letsas KP, Tse G, Fragakis N, Goudis CA, Liu T. Inflammation and atrial fibrillation: a comprehensive review. *J Arrhythm*. 2018;34(4):394–401.
- 45 Newman AB, Gottdiener JS, McBurnie MA, Hirsch CH, Kop WJ, Tracy R, et al. Associations of subclinical cardiovascular disease with frailty. *J Gerontol A Biol Sci Med Sci*. 2001;56(3):M158–66.
- 46 Canon M, Crimmins E. Sex differences in the association between muscle quality, inflammatory markers, and cognitive decline. *J Nutr Health Aging*. 2011;15(8):695–8.
- 47 Gale CR, Baylis D, Cooper C, Sayer AA. Inflammatory markers and incident frailty in men and women: the English Longitudinal Study of Ageing. *Age*. 2013;35(6):2493–501.
- 48 Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. *J Am Coll Cardiol*. 2012;60(22):2263–70.
- 49 Smit MD, Maass AH, De Jong AM, Muller Kobold AC, Van Veldhuisen DJ, Van Gelder IC. Role of inflammation in early atrial fibrillation recurrence. *Europace*. 2012;14(6):810–7.
- 50 Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. *CMAJ*. 2005 Aug 30;173(5):489–95.